Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aumolertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | MLNR | O43193 | 1/20 | 0.82 |
| ▸ | KDM1A | O60341 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.82 |
| ▸ | INSR | P06213 | 1/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | DRD2 | P14416 | 1/20 | 0.82 |
| ▸ | NQO2 | P16083 | 1/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.82 |
| ▸ | HTR2C | P28335 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aumolertinib SCHEMBL29389482 | 1.00 | EGFR (1.00) | EGFRKCNH2MLNRKDM1AABCB11 | |
| Aumolertinib SCHEMBL30341838 | 0.99 | EGFR (0.99) | EGFRKCNH2MLNRKDM1AABCB11 | |
| Aumolertinib SCHEMBL29786118 | 0.97 | EGFR (0.95) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL17683054 | 0.94 | EGFR (1.00) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL30108191 | 0.94 | EGFR (0.88) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL28942076 | 0.94 | EGFR (0.88) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL30459752 | 0.93 | EGFR (0.88) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL19532567 | 0.93 | EGFR (0.88) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL17683226 | 0.93 | EGFR (0.88) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL17683092 | 0.93 | EGFR (0.87) | EGFRKCNH2MLNRKDM1AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370448-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THIRD GENERATION SMALL MOLECULE EGFR INHIBITOR AND PREPARATION METHOD THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-11-24 | — | — | US | claimed |
| US-11155534-B2 | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-10-26 | — | — | US | claimed |
| EP-3795157-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SMALL MOLECULE EGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-03-24 | — | — | EP | claimed |
| US-20210069190-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SMALL MOLECULE EGFR INHIBITOR AND PREPARATION METHOD THEREFOR | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-03-11 | — | — | US | claimed |
| EP-3434673-B1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2021-02-17 | — | — | EP | claimed |
| US-20200361909-A1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-11-19 | — | — | US | claimed |
| US-10759782-B2 | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-01 | — | — | US | claimed |
| US-20190077791-A1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-03-14 | — | — | US | claimed |
| EP-3434673-A1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | claimed |
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | disclosed |
| US-20250325543-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | ASTRAZENECA AB (SE) | 2025-10-23 | — | — | US | disclosed |
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DE) | 2025-09-04 | — | — | US | disclosed |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-07-03 | — | — | US | disclosed |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-06-26 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2017161937-A1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | 江苏豪森药业集团有限公司 | 2017-09-28 | — | — | WO | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016054987-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | MAPT, PSEN2, PSEN1 | EGFR 4305/4885KCNH2 4624/4885MLNR 4599/4885 |
| US-10759782-B2 | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | EGFR, WEE1, SLC38A7 | EGFR 1/4885KCNH2 1883/4885MLNR 801/4885 |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885KCNH2 4088/4885MLNR 166/4885 |
| US-20200361909-A1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | EGFR, WEE1, SLC38A7 | EGFR 1/4885KCNH2 1883/4885MLNR 801/4885 |
| US-20190077791-A1 | EGFR INHIBITOR FREE BASE OR ACID SALT POLYCRYSTALLINE FORM, PREPARATION METHOD THEREFOR, AND APPLICATION | EGFR, WEE1, SLC38A7 | EGFR 1/4885KCNH2 1883/4885MLNR 801/4885 |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | EGFR 1/4885KCNH2 4834/4885MLNR 678/4885 |
| US-20220370448-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THIRD GENERATION SMALL MOLECULE EGFR INHIBITOR AND PREPARATION METHOD THEREOF | EGFR, ERBB3, ERBB2 | EGFR 1/4885KCNH2 3776/4885MLNR 185/4885 |
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | EGFR 3/4885KCNH2 4499/4885MLNR 1925/4885 |
| US-20250325543-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | EGFR, ERBB2, ERBB4 | EGFR 1/4885KCNH2 4306/4885MLNR 865/4885 |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, SDHA | EGFR 894/4885KCNH2 3918/4885MLNR 3168/4885 |
| US-11155534-B2 | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | EGFR, WEE1, SLC38A7 | EGFR 1/4885KCNH2 1883/4885MLNR 801/4885 |
| US-20210069190-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SMALL MOLECULE EGFR INHIBITOR AND PREPARATION METHOD THEREFOR | EGFR, ERBB2, ERBB3 | EGFR 1/4885KCNH2 4168/4885MLNR 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.